- Home
- SNAL vs EDIT Comparison
SNAL vs EDIT Comparison
Compare SNAL & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNAL
- EDIT
- Stock Information
- Founded
- SNAL 2000
- EDIT 2013
- Country
- SNAL United States
- EDIT United States
- Employees
- SNAL N/A
- EDIT N/A
- Industry
- SNAL Computer Software: Prepackaged Software
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNAL Technology
- EDIT Health Care
- Exchange
- SNAL Nasdaq
- EDIT Nasdaq
- Market Cap
- SNAL 92.8M
- EDIT 108.1M
- IPO Year
- SNAL 2022
- EDIT 2016
- Fundamental
- Price
- SNAL $2.09
- EDIT $1.92
- Analyst Decision
- SNAL
- EDIT Buy
- Analyst Count
- SNAL 0
- EDIT 14
- Target Price
- SNAL N/A
- EDIT $8.08
- AVG Volume (30 Days)
- SNAL 104.1K
- EDIT 5.8M
- Earning Date
- SNAL 03-31-2025
- EDIT 03-03-2025
- Dividend Yield
- SNAL N/A
- EDIT N/A
- EPS Growth
- SNAL N/A
- EDIT N/A
- EPS
- SNAL 0.08
- EDIT N/A
- Revenue
- SNAL $86,822,973.00
- EDIT $61,759,000.00
- Revenue This Year
- SNAL $39.43
- EDIT N/A
- Revenue Next Year
- SNAL $26.12
- EDIT N/A
- P/E Ratio
- SNAL $27.65
- EDIT N/A
- Revenue Growth
- SNAL 82.23
- EDIT 150.95
- 52 Week Low
- SNAL $0.52
- EDIT $1.12
- 52 Week High
- SNAL $3.42
- EDIT $11.58
- Technical
- Relative Strength Index (RSI)
- SNAL 45.01
- EDIT 55.72
- Support Level
- SNAL $2.15
- EDIT $1.12
- Resistance Level
- SNAL $3.42
- EDIT $3.30
- Average True Range (ATR)
- SNAL 0.31
- EDIT 0.30
- MACD
- SNAL -0.08
- EDIT 0.12
- Stochastic Oscillator
- SNAL 9.52
- EDIT 36.70
About SNAL Snail Inc.
Snail Inc is a global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.